Petrylak DP - Search Results

1

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

Petrylak DP, Macarthur R, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Hetjan D, Sawczuk I, Benson M, Olsson C. Petrylak DP, et al. Semin Oncol. 1999 Oct;26(5 Suppl 17):28-33. Semin Oncol. 1999. PMID: 10604266 Clinical Trial.

2

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Seidman AD, et al. J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8. J Urol. 1992. PMID: 1371564 Clinical Trial.

3

Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy.

Petrylak DP, Scher HI, Li Z, Myers CE, Geller NL. Petrylak DP, et al. Cancer. 1992 Dec 15;70(12):2870-8. doi: 10.1002/1097-0142(19921215)70:12<2870::aid-cncr2820701225>3.0.co;2-f. Cancer. 1992. PMID: 1451069

4

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer.

Yagoda A, Petrylak D. Yagoda A, et al. Cancer. 1993 Feb 1;71(3 Suppl):1098-109. doi: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g. Cancer. 1993. PMID: 7679039 Review.

5

Chemotherapy for advanced renal-cell carcinoma: 1983-1993.

Yagoda A, Abi-Rached B, Petrylak D. Yagoda A, et al. Semin Oncol. 1995 Feb;22(1):42-60. Semin Oncol. 1995. PMID: 7855619 Review. No abstract available.

6

Transferrin receptor expression in testis cancer.

Petrylak DP, Yagoda A, O'Toole KM, Chadburn A, Sawczuk IS, Benson MC, Olsson CA, Allegretta L, Saad AD, Wartinger DD. Petrylak DP, et al. J Natl Cancer Inst. 1994 Apr 20;86(8):636-7. doi: 10.1093/jnci/86.8.636-a. J Natl Cancer Inst. 1994. PMID: 8145279 No abstract available.

7

Cytotoxic chemotherapy for advanced renal cell carcinoma.

Yagoda A, Petrylak D, Thompson S. Yagoda A, et al. Urol Clin North Am. 1993 May;20(2):303-21. Urol Clin North Am. 1993. PMID: 8493752 Review.

8

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.

Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA. Petrylak DP, et al. J Clin Oncol. 1999 Mar;17(3):958-67. doi: 10.1200/JCO.1999.17.3.958. J Clin Oncol. 1999. PMID: 10071290 Clinical Trial.

9

Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients.

Lee N, Newhouse JH, Olsson CA, Benson MC, Petrylak DP, Schiff PB, Bagiella E, Malyszko B, Ennis RD. Lee N, et al. Among authors: petrylak dp. Urology. 1999 Sep;54(3):490-4. doi: 10.1016/s0090-4295(99)00150-8. Urology. 1999. PMID: 10475360

10

Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.

Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D. Hussain M, et al. Semin Oncol. 1999 Oct;26(5 Suppl 17):55-60. Semin Oncol. 1999. PMID: 10604271

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

300 results

Search Page

Filters